Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations

Bernadett Márkus, Krisztián Vörös, Dorina Supák, Zsolt Melczer, K. Cseh, L. Kalabay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Both peroxisome activator proteins (PPARs) and fetuin-A play a role in lipid and glucose metabolism. Aims. We investigated whether PPARα intron 7 G2468/C and PPARγ2 Pro12Ala and PPARγ exon 6 C161T polymorphisms are associated with serum fetuin-A concentrations. Patients and Methods. The PPARα intron 7 G/C polymorphism was studied in cohort 1 (79 reference individuals, 165 postinfarction patients). The two PPARγ polymorphisms were investigated in cohort 2 (162 reference individuals, 165 postinfarction patients). Fetuin-A levels and PPAR polymorphisms were determined by radial immunodiffusion and polymerase chain reaction-restriction fragment length polymorphism techniques. Results. The C allele variant of PPARα intron 7 G2467C was associated with higher fetuin-A levels (p=0.018). Postinfarction status (p=0.001), PPARα intron 7 GG/GC/CC genotypes (p=0.032), and the C allele (p=0.021) were the strongest determinants of fetuin-A concentration in a multiple regression model. Higher fetuin-A levels were associated with the Pro variant of PPARγ2 (p=0.047). Postinfarction status (p=0.041) and BMI (p<0.001) but not PPARγ2 Pro were the strongest determinants of fetuin-A concentrations. PPARγ exon 6 C161T genotypes were not associated with fetuin-A levels. Conclusions. Fetuin-A was determined mainly by the PPARα intron 7C allele and postinfarction status in cohort 1 and the BMI and postinfarction in cohort 2. The PPARα intron 7C and PPARγ2 Pro variants are associated with fetuin-A levels.

Original languageEnglish
Article number7636019
JournalPPAR Research
Volume2017
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

alpha-2-HS-Glycoprotein
PPAR alpha
Peroxisome Proliferator-Activated Receptors
PPAR gamma
Introns
Serum
Alleles
Exons
Genotype
Peroxisomes
Immunodiffusion
Lipid Metabolism
Restriction Fragment Length Polymorphisms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology (medical)

Cite this

Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations. / Márkus, Bernadett; Vörös, Krisztián; Supák, Dorina; Melczer, Zsolt; Cseh, K.; Kalabay, L.

In: PPAR Research, Vol. 2017, 7636019, 01.01.2017.

Research output: Contribution to journalArticle

@article{7a1628de83c9480aab549c0a5209717c,
title = "Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations",
abstract = "Background. Both peroxisome activator proteins (PPARs) and fetuin-A play a role in lipid and glucose metabolism. Aims. We investigated whether PPARα intron 7 G2468/C and PPARγ2 Pro12Ala and PPARγ exon 6 C161T polymorphisms are associated with serum fetuin-A concentrations. Patients and Methods. The PPARα intron 7 G/C polymorphism was studied in cohort 1 (79 reference individuals, 165 postinfarction patients). The two PPARγ polymorphisms were investigated in cohort 2 (162 reference individuals, 165 postinfarction patients). Fetuin-A levels and PPAR polymorphisms were determined by radial immunodiffusion and polymerase chain reaction-restriction fragment length polymorphism techniques. Results. The C allele variant of PPARα intron 7 G2467C was associated with higher fetuin-A levels (p=0.018). Postinfarction status (p=0.001), PPARα intron 7 GG/GC/CC genotypes (p=0.032), and the C allele (p=0.021) were the strongest determinants of fetuin-A concentration in a multiple regression model. Higher fetuin-A levels were associated with the Pro variant of PPARγ2 (p=0.047). Postinfarction status (p=0.041) and BMI (p<0.001) but not PPARγ2 Pro were the strongest determinants of fetuin-A concentrations. PPARγ exon 6 C161T genotypes were not associated with fetuin-A levels. Conclusions. Fetuin-A was determined mainly by the PPARα intron 7C allele and postinfarction status in cohort 1 and the BMI and postinfarction in cohort 2. The PPARα intron 7C and PPARγ2 Pro variants are associated with fetuin-A levels.",
author = "Bernadett M{\'a}rkus and Kriszti{\'a}n V{\"o}r{\"o}s and Dorina Sup{\'a}k and Zsolt Melczer and K. Cseh and L. Kalabay",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/7636019",
language = "English",
volume = "2017",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Association of PPAR Alpha Intron 7 G/C, PPAR Gamma 2 Pro12Ala, and C161T Polymorphisms with Serum Fetuin-A Concentrations

AU - Márkus, Bernadett

AU - Vörös, Krisztián

AU - Supák, Dorina

AU - Melczer, Zsolt

AU - Cseh, K.

AU - Kalabay, L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background. Both peroxisome activator proteins (PPARs) and fetuin-A play a role in lipid and glucose metabolism. Aims. We investigated whether PPARα intron 7 G2468/C and PPARγ2 Pro12Ala and PPARγ exon 6 C161T polymorphisms are associated with serum fetuin-A concentrations. Patients and Methods. The PPARα intron 7 G/C polymorphism was studied in cohort 1 (79 reference individuals, 165 postinfarction patients). The two PPARγ polymorphisms were investigated in cohort 2 (162 reference individuals, 165 postinfarction patients). Fetuin-A levels and PPAR polymorphisms were determined by radial immunodiffusion and polymerase chain reaction-restriction fragment length polymorphism techniques. Results. The C allele variant of PPARα intron 7 G2467C was associated with higher fetuin-A levels (p=0.018). Postinfarction status (p=0.001), PPARα intron 7 GG/GC/CC genotypes (p=0.032), and the C allele (p=0.021) were the strongest determinants of fetuin-A concentration in a multiple regression model. Higher fetuin-A levels were associated with the Pro variant of PPARγ2 (p=0.047). Postinfarction status (p=0.041) and BMI (p<0.001) but not PPARγ2 Pro were the strongest determinants of fetuin-A concentrations. PPARγ exon 6 C161T genotypes were not associated with fetuin-A levels. Conclusions. Fetuin-A was determined mainly by the PPARα intron 7C allele and postinfarction status in cohort 1 and the BMI and postinfarction in cohort 2. The PPARα intron 7C and PPARγ2 Pro variants are associated with fetuin-A levels.

AB - Background. Both peroxisome activator proteins (PPARs) and fetuin-A play a role in lipid and glucose metabolism. Aims. We investigated whether PPARα intron 7 G2468/C and PPARγ2 Pro12Ala and PPARγ exon 6 C161T polymorphisms are associated with serum fetuin-A concentrations. Patients and Methods. The PPARα intron 7 G/C polymorphism was studied in cohort 1 (79 reference individuals, 165 postinfarction patients). The two PPARγ polymorphisms were investigated in cohort 2 (162 reference individuals, 165 postinfarction patients). Fetuin-A levels and PPAR polymorphisms were determined by radial immunodiffusion and polymerase chain reaction-restriction fragment length polymorphism techniques. Results. The C allele variant of PPARα intron 7 G2467C was associated with higher fetuin-A levels (p=0.018). Postinfarction status (p=0.001), PPARα intron 7 GG/GC/CC genotypes (p=0.032), and the C allele (p=0.021) were the strongest determinants of fetuin-A concentration in a multiple regression model. Higher fetuin-A levels were associated with the Pro variant of PPARγ2 (p=0.047). Postinfarction status (p=0.041) and BMI (p<0.001) but not PPARγ2 Pro were the strongest determinants of fetuin-A concentrations. PPARγ exon 6 C161T genotypes were not associated with fetuin-A levels. Conclusions. Fetuin-A was determined mainly by the PPARα intron 7C allele and postinfarction status in cohort 1 and the BMI and postinfarction in cohort 2. The PPARα intron 7C and PPARγ2 Pro variants are associated with fetuin-A levels.

UR - http://www.scopus.com/inward/record.url?scp=85026531212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026531212&partnerID=8YFLogxK

U2 - 10.1155/2017/7636019

DO - 10.1155/2017/7636019

M3 - Article

AN - SCOPUS:85026531212

VL - 2017

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 7636019

ER -